These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29722587)

  • 21. Use of cariprazine in psychiatric disorders: A systematic review.
    Chhatlani A; Farheen SA; Setty MJ; Tampi RR
    Ann Clin Psychiatry; 2018 Nov; 30(4):326-334. PubMed ID: 30372510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cariprazine in Bipolar Depression and Mania: State of the Art.
    Mazza M; Marano G; Traversi G; Carocci V; Romano B; Janiri L
    CNS Neurol Disord Drug Targets; 2018; 17(10):723-727. PubMed ID: 30152291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.
    Watson DJG; King MV; Gyertyán I; Kiss B; Adham N; Fone KCF
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):208-224. PubMed ID: 26723167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.
    Marder S; Fleischhacker WW; Earley W; Lu K; Zhong Y; Németh G; Laszlovszky I; Szalai E; Durgam S
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):127-136. PubMed ID: 30470662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetics of Cariprazine and its Major Metabolites.
    Periclou A; Phillips L; Ghahramani P; Kapás M; Carrothers T; Khariton T
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):53-69. PubMed ID: 33141308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania.
    Tarazi FI; Neill JC
    Expert Opin Drug Discov; 2013 Jan; 8(1):93-103. PubMed ID: 23121334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia.
    Riccobene T; Riesenberg R; Yeung PP; Earley WR; Hankinson AL
    J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):434-443. PubMed ID: 36282772
    [No Abstract]   [Full Text] [Related]  

  • 31. Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.
    Seneca N; Finnema SJ; Laszlovszky I; Kiss B; Horváth A; Pásztor G; Kapás M; Gyertyán I; Farkas S; Innis RB; Halldin C; Gulyás B
    Psychopharmacology (Berl); 2011 Dec; 218(3):579-87. PubMed ID: 21625907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action of cariprazine.
    Stahl SM
    CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
    Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
    BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia.
    Misiak B; Bieńkowski P; Samochowiec J
    Psychiatr Pol; 2018 Dec; 52(6):971-981. PubMed ID: 30659560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis.
    Durgam S; Earley W; Lu K; Németh G; Laszlovszky I; Volk S; Litman RE
    Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29119668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.
    Tarazi FI; Riva MA
    Expert Opin Drug Discov; 2013 Oct; 8(10):1297-307. PubMed ID: 23837554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data.
    Tohen M
    Drug Des Devel Ther; 2021; 15():2005-2012. PubMed ID: 34012253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine D3 Receptors: From Bench to Bedside.
    Gonda X; Tarazi FI
    Neuropsychopharmacol Hung; 2021 Jun; 23(2):272-280. PubMed ID: 34342419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.